Research programme: interleukin-1 receptor antagonists - SerodusAlternative Names: SER-140; SER-140-T2D
Latest Information Update: 20 Jan 2016
At a glance
- Originator Phlogo
- Developer Serodus
- Class Peptides
- Mechanism of Action Interleukin 1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus